Boehringer obesity drug cuts harmful fat while preserving lean mass

Boehringer Ingelheim is pitching survodutide as more than a scale-moving obesity shot. In late-stage data, the experimental drug cut visceral fat by as much as 34% and liver fat by as much as 63.1%, while lean mass accounted for no more than 10.8% of the total body-composition change at the highest dose.

That distinction matters in a market where obesity treatments are increasingly judged by what they do to heart, liver and metabolic risk, not just body weight. The company said the findings were presented at the American Diabetes Association’s 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine. Survodutide, also known as BI 456906, is a once-weekly subcutaneous dual agonist that acts on glucagon and GLP-1 receptors.

In the main SYNCHRONIZE-1 trial, adults taking survodutide lost up to an average of 16.6% of body weight after 76 weeks, compared with 3.2% on placebo. Boehringer said 85.1% of treated patients achieved at least 5% weight loss, versus 38.8% on placebo, and the study met its co-primary endpoints. The company also said waist circumference, a key secondary endpoint, improved, underscoring the focus on central obesity rather than headline pounds alone.

The sharper argument for survodutide comes from liver data. In a separate late-stage study of people with overweight or obesity and metabolic dysfunction-associated steatotic liver disease, or MASLD, 84.2% of treated patients achieved at least a 30% reduction in liver fat, compared with 24.3% on placebo. Liver fat normalized in 61% of treated patients, versus 5.7% on placebo, and Boehringer said 6 out of 10 participants reached normalization after 48 weeks. Shashank Deshpande, a Boehringer executive, said, "We believe survodutide will become an important new option at the intersection of obesity and liver disease."

For now, the drug still faces the same commercial and clinical test that confronts all obesity medicines: tolerability. Boehringer said 19% of participants in SYNCHRONIZE-1 discontinued because of gastrointestinal adverse events, compared with 2.9% on placebo. The most common side effects were nausea, vomiting, diarrhea and constipation. That rate of dropouts is a reminder that even impressive fat-loss data must be balanced against how well patients can stay on therapy.

Boehringer, which licensed survodutide from Zealand Pharma, said it is solely responsible for global development and commercialization. Zealand is eligible for high single- to low double-digit royalties on global sales, plus EUR 315 million in potential milestone payments. The drug is still being tested in additional phase 3 programs, including cardiovascular and liver-disease studies, and remains a step away from challenging the standard set by Novo Nordisk and Eli Lilly.